The aim of this study is to determine the contribution of neck and chest Tc-pertechnetate-nonavid metastases.
I administration, a total of 184 postoperative DTC patients with stimulated serum thyroglobulin (ssTg) >10 ng/mL were enrolled to undergo neck and chest Tc-pertechnetate-avid group (n = 13) decreased significantly compared with that in 99m Tc-pertechnetate-nonavid group (n = 59) (median: À81.56% vs À48.14%; Z = À4.276, P = .000). The difference of therapeutic response between Tc-pertechnetate-nonavid metastases.
Introduction
Differentiated thyroid cancers (DTCs) are typically iodine-avid and can be effectively treated with radioiodine ( 131 I) when persistent/recurrent or metastatic disease are not amenable to surgery. [1] [2] [3] [4] In this context, a diagnostic 131 I whole body scan (Dx-WBS) may be useful to detect iodine-avid metastases before 131 I therapy, allowing a more precise selection of therapeutic candidate and appropriate activity of 131 I. If metastases are detected in Dx-WBS, then the prescribed 131 I activity can be increased to maximize therapeutic success at first 131 I treatment. [5] [6] [7] However, specialists who favor post-therapeutic 131 I whole body scan (Rx-WBS) argue that scans performed after therapeutic activity of 131 I administration are more sensitive for disease detection and avoid possible stunning of thyroid remnants and distant metastases from thyroid cancer. [8] [9] [10] [11] [12] Until now the real mechanism of stunning effect has not been known. Some researchers also found molecular-level evidence that the stunning effect exists even at a low activity of 131 I, which further hampered the use of Dx-WBS before 131 I therapy. [13] Rx-WBS possibly neglect sufficient radiation activity to metastatic lesions during Editor: Eleonore Fröhlich.
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the first course of 131 I therapy since disease was not determined timely. [14] 99m Tc-pertechnetate has been widely applied to evaluate thyroid diseases because of its ideal imaging characteristics and favorable price and dosimetry. Pertechnetate-avid metastatic lesions from DTC have been described by several case reports. [15] [16] [17] [18] However, only 3 comparative studies with 131 I can be retrieved, mainly focusing on the diagnostic efficiency of 99m Tc-pertechnetate scan for thyroid remnant. [19] [20] [21] To date, the value of 99m Tc-pertechnetate scan (planar scan combined with SPECT/CT [single photon emission computed tomography/ computed tomography]) in the management of DTC patients has not been adequately assessed. The relationship between the therapeutic response to 131 I and the avidity of metastatic lesions for 99m Tc-pertechnetate is still unknown. Here, we therefore, designed a dedicated study to determine the contribution of neck and chest 99m Tc-pertechnetate scan to the management of postoperative DTC patients with suspicious metastatic lesions.
Subjects and methods

Study design and population
This study was approved by the ethics board of Shanghai Jiao Tong University Affiliated Sixth People's Hospital before its initiation (No. 2014--0013). All participants were informed of details of the study with the information sheet and had signed the consent form prior to their inclusion in the study.
We prospectively evaluated 184 consecutive patients with DTC who were considered to have suspicious metastatic disease after total or nearly total thyroidectomy (≥4 weeks) based on elevated stimulated serum thyroglobulin (ssTg) levels >10 ng/mL, with thyroid-stimulating hormone (TSH) level >30 mIU/mL. All patients were confirmed with lymph node (LN) metastasis by the pathology of thyroidectomy. Patients with a history of malignant tumor other than DTC were excluded from the study. Thyroxine withdrawal and low-iodine diet for at least 4 week were required before blood samples were drawn and 131 I administered. Serum TSH, Tg, and Tg-antibody levels were measured using a chemiluminescent immunoassay system (Immulite, Diagnostic Products Corp., Los Angeles, CA). Empirically fixed dose of 131 I was given at 5.5 GBq for patients with local or suspected disease and 7.4 GBq for patients with distant metastases. All patients underwent neck and chest 99m Tc-pertechnetate planar scan with SPECT/CT just before 131 I administration or switch to reoperation.
Imaging protocol and image analyses
99m Tc-pertechnetate planar scan in neck and chest was performed 15 min after intravenous injection of 99m Tc-pertechnetate (370 MBq). The neck and chest SPECT/CT images were obtained using a hybrid SPECT/CT imaging system (Millennium VG and Hawkeye, GE Healthcare). The Rx-WBS and SPECT/CT were carried out 5 days after administration of 131 I with the same technique equipped with a high-energy collimator. The detailed parameters have been described previously by our team. [22] Two experienced nuclear medicine physicians, who were aware of the results of all relevant examinations, laboratory investigations, and imaging studies, evaluated the 99m Tcpertechnetate scans and came to an agreement by consensus. The Rx-WBS with SPECT/CT was reviewed by other 2 nuclear medicine physicians who did not know the previous pretreatment pertechnetate scans. Foci of radioactivity identified on planar imaging were further evaluated on SPECT/CT and classified according to their location and nature as positive scan, which was defined as anatomical finding from CT with increased radiotracer uptake higher than surrounding background excluding thyroid remnant or physiological distribution; equivocal scan, which included the following situations: abnormal anatomical localization from CT without unnatural increased radiotracer uptake or increased radiotracer uptake without corresponded anatomical finding from CT excluding thyroid remnant; and neither increased radiotracer uptake nor unnatural anatomical foci from CT excluding thyroid remnant were considered as negative scan.
Concordant rate of per-patient and per-lesion basis was analyzed and the strength of agreement was obtained using unweighted kappa statistical analysis. According to the therapeutic response assessment system proposed by 2015 American Thyroid Association guidelines, we analyzed the clinical data obtained during follow-up and divided all patients who experienced at least 2 dose of 131 I therapy into 4 categories: excellent response (ER), indeterminate response (IDR), biochemical incomplete response (BIR), and structural incomplete response (SIR) during follow-up. [2] 
Assessment during follow-up
Statistical analyses
All statistical analyses were performed using a statistical software program (SPSS, version 16.0; SPSS, Inc Chicago, IL). The parameters such as age at diagnosis, sex, subtype of DTC, 131 I activity, ssTg level, and the percentage change in ssTg were analyzed by univariate analysis and confirmed by the x 2 test or Wilcoxon rank sum tests or Student t test. The correlation of the percentage changes in ssTg between pertechnetate-avid group and pertechnetate-nonavid group were evaluated using the Spearman rank correlation. Fisher exact test was used to test the statistical significance of categorical data. All P values reported were 2-sided, and a P value of less than .05 was considered significant.
Results
Patient demographic and baseline characteristics
Patient demographic and baseline characteristics are summarized in Table 1 Data are expressed as n (%) unless otherwise stated. ssTg = stimulated serum thyroglobulin, TNM = tumor, node, metastasis, TSH = thyroid-stimulating hormone. I findings were revealed in 27 and 26 patients, respectively. Thus, the percentage of concordance was 70.2% (125/178) with the unweighted kappa of 0.257. In lung, positive, equivocal, and negative findings by both 99m Tc-pertechnetate and 131 I scans were found in 2, 4, and 160 patients. There were 12 patients who showed negative (n = 8)/equivocal (n = 4) 99m Tcpertechnetate but positive 131 I scan. So, the percentage of concordance was 93.2% (166/178) with the unweighted kappa of 0.518. In bone, there were only 5 patients who were defined as positive on 131 I scan but equivocal on 99m Tc-pertechnetate scan, yielding a percentage of concordance of 0% with the unweighted kappa of 0.
Per-site analysis
There were a total of 30 positive metastatic foci on 99m Tcpertechnetate scan. Of these, 21 foci were located in LNs (Fig. 1) , 9 foci in lung nodules (Fig. 2) (n = 13), and pertechnetate-nonavid group (n = 59) were analyzed, and no differences were observed. The percentage changes in ssTg levels between pertechnetate-avid group and pertechnetate-nonavid group were compared ( Table 3) . As a result, ssTg decreased 81.56% ± 31.22% (median ± interquartile range) in pertechnetate-avid group and 48.14% ± 44.70% (median ± interquartile range) in pertechnetate-nonavid group with statistical significance (Z = À4.276; P = .000) and correlation (r = 0.506; P = .000). During the follow-up with a median duration of 13.4 months after the first 131 I therapy, the proportion of ER, IDR, BIR, and SIR in 99m Tc-pertechnetate-avid group amounted to 61.5% (8/ 13), 15.4% (2/13), 7.7% (1/13), and 15.4% (2/13), respectively. In 99m Tc-pertechnetate-nonavid group, 21.3% (13/61), 29.5% (18/61), 32.8% (20/61), and 24.6% (15/61) of patients were categorized to ER, IDR, BIR, and SIR, respectively. The difference of therapeutic response between 99m Tc-pertechnetate-avid group and 99m Tc-pertechnetate-nonavid group was statistically significant (x 2 = 8.4; P = .03).
Discussion
The assessment of postoperative disease status has vital role in the management of advanced DTC patients. [2, 23] The likelihood of identifying either loco-regional recurrent/persistent disease or distant metastases on the Rx-WBS increases as either the suppressed or ssTg values rise above 5 to 10 ng/mL. [24, 25] However, the localization of metastatic DTC lesions commonly falls back on imaging modalities. Although ultrasonography is very sensitive for the identification of cervical nodal compartments metastases, the specificity is low and the prescribed regions are limited, which impedes its use in the identification of distant metastases. [26, 27] Meanwhile, controversies on the utility of Dx-WBS in guiding 131 I therapeutic decision making still exist, and predictors on the outcome of 131 I therapy of DTC are unavailable at present. [2] 99m Tc-pertechnetate is a monovalent anion similar to iodide and can be accumulated by sodium/iodide symporter located in the membrane of thyroidal cytes. Theoretically, visualization of metastatic deposits on pertechnetate scans can hint at their strong capacity to concentrate 131 I and therefore assure the potential to respond to 131 I therapy. [17] However, there is limited literature describing the value of pertechnetate scans in detecting metastatic disease, and its clinical implication has not been fully assessed. [16] [17] [18] 20] Our group demonstrated that the information obtained at the time of 99m Tc-pertechnetate scans led to a change in management decision in 19/184 (10.3%) patients, including referral for resection (n = 6) or alternating the prescribed I-avid foci in the Rx-SPECT/CT, we found that ssTg in pertechnetate-avid group decreased more significantly than in pertechnetate-nonavid group. Furthermore, the difference of therapeutic response between the 2 groups was also statistically significant. It suggests that in patients with 131 I-avid metastases, more favorable therapeutic response to 131 I therapy may be obtained in pertechnetate-avid group compared with pertechnetate-nonavid group. This can be explained by that 99m Tc-pertechnetate-avid lesions may concentrate more 131 I than those nonavid for 99m Tcpertechnetate, yielding a higher radiation dose. [22, 28] Besides, our study also demonstrates that the percentages of concordance Tc-pertechnetate can be concentrated by thyroid follicular cells, but do not undergo the organification process, which might cause insufficient visualization because of lower accumulation and target/background ratio and much shorter deposit time compared with 131 I. [22, 28, 29] Our findings on the diagnostic value of 99m Tc-pertechnetate scan are inconsistent with study by Chantadisai et al, which demonstrated that preablative 99m Tc-pertechnetate planar scan with neck and chest SPECT/CT has good correlation with posttherapeutic 131 I planar scan with SPECT/CT per-patient basis. [20] However, our group reports a relatively lower overall patientbased or lesion-based percentage of concordance. The possible explanation is that our study focused mainly on metastatic lesions, but Chantadisai et al cared mainly about thyroid remnant (92.2%). Other studies have also revealed that postoperative 99m Tc-pertechnetate scan has a high positive predictive value to detect remnant tissue in DTC patients in the literature. [19, 21, [29] [30] [31] Their studies were limited to scan of the thyroid bed, so no comments can be made about the value of 99m Tc-pertechnetate scan in detecting extrathyroidal or metastatic sites. Additionally, a low sensitivity of 99m Tc-pertechnetate scan compared with diagnostic 131 I WBS in detecting extrathyroidal and metastatic disease was report in 1990 with an obvious limitation of very small sample size as 5. [32] Different from the previous reports, our study focused on the value of 99m Tc-pertechnetate neck and chest planar scan combined with SPECT/CT in the management of patients with suspicious metastatic DTCs post-total or near total thyroidectomy in a much larger size of sample.
The pertechnetate avidity of metastatic deposits beyond thyroid bed determined by SPECT can provide features of lesions and has incremental value over planar scan in increasing diagnostic accuracy, reducing pitfalls, and yielding a specific diagnosis. Meanwhile, the CT component of hybrid SPECT/CT can be used to determine the location and size of metastatic lesions without radiotracer uptake. [22] Therefore, proceeding with a 99m Tc-pertechnetate planar scan combined with SPECT/ CT may lead to cost savings and streamlined management decisions in patients with suspicious metastases.
Inevitably, there were some limitations in our study. We did not compare 99m Tc-pertechnetate scan to diagnostic scan using low activity 131 I in this series directly. Besides, the value of 99m Tcpertechnetate scan in patients with metastases in other sites beyond neck and chest is still unknown. Finally, we admit that assessing the outcome of therapeutic interventions requires prolonged follow-up in this relatively indolent malignancy, studies with longer follow-ups are still needed. 
